[ Price : $8.95]
Roche reports positive Phase 3 lidERA trial results for its giredestrant selective estrogen receptor degrader endocrine therapy in...[ Price : $8.95]
Reuters reports that Daniel McMullen, the former director of the CDRH Office of Neurological and Physical Medicine Devices, has jo...[ Price : $8.95]
CBER officials pen a new JAMA article signaling a major policy shift for cancer CAR T-cell therapies, moving away from reliance on...[ Price : $8.95]
Four Hogan Lovells attorneys describe a potential significant shift in Justice Department enforcement boundaries, especially invol...[ Price : $8.95]
FDA warns Massena, NY-based Seaway Pharma about long-standing CGMP violations in its production of finished drugs as a contract ma...[ Price : $8.95]
FDA approves Augmentin XR (amoxicillinclavulanate potassium) through the new Commissioners National Priority Voucher pilot program...[ Price : $8.95]
CDER issues a Manual of Policies and Procedures for when a reference-listed drug switches from prescription to nonprescription mar...[ Price : $8.95]
FDA qualifies its first artificial intelligence drug development tool, which will be used in metabolic dysfunction-associated stea...